Sector News

Sun Pharma to buy Concert Pharmaceuticals for $576m

January 22, 2023
Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m.

Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

Additionally, the stockholders of Concert will receive a contingent value right (CVR), based on the net sales milestones of deuruxolitinib, entitling them to up to $3.50 per share of common stock in cash.

Concert’s patent portfolio includes oral Janus kinases JAK1/2 inhibitor, deuruxolitinib, to treat Alopecia Areata, an autoimmune dermatological disease.

Deuruxolitinib’s safety and efficacy were assessed in moderate to severe Alopecia Areata adult patients in the THRIVE-AA Phase III clinical programme.

It is currently being evaluated in two open-label, long-term extension trials in North America and Europe.

Sun Pharma stated that it would follow Concert’s plan to seek approval from the US Food and Drug Administration (FDA) for its new drug application in the first half of the year.

The company also noted that the deal would strengthen its global dermatology franchise by adding a late-stage product in an area with significant unmet needs.

Sun Pharma North America CEO Abhay Gandhi said: “Sun Pharma is building a global Dermatology and Ophthalmology franchise and aims to be a preferred development and commercial partner in these therapies worldwide.

“The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib.

“There is a significant unmet need in the Alopecia Areata space, and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.”

The transaction, subject to regulatory approvals and other customary closing conditions, is anticipated to be concluded in the first quarter of this year.

Source: pharmaceutical-technology.com

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach